Anthropic's Foray into Drug Design Sparks Heated Debate
PatrickKidger · x · 2026-07-05
Anthropic's entry into drug design (AIxBio) has sparked controversy within the biopharma community. Pessimists question the move, citing that "drug design is hard," "they shouldn't compete with customers," and that "if they really want to do it, they should acquire Cradle or Boltz." ML researcher Patrick Kidger publicly countered these views, stating that despite Anthropic starting behind the AIxBio SOTA and needing to tackle difficult coursework, he is still excited by capable people stepping up to solve these problems, believing it could be the start of something remarkable.
More from Companies & People
- 7 Bittensor Subnets Accepted into NVIDIA Inception, Making Up 21% of Cohort — markjeffrey · 2026-07-27
- AI lab staff have gone strangely quiet about next-year capability predictions — ChrisGPT · 2026-07-27
- Anthropic faces renewed culture backlash over alleged open-source AI screening — rdesh26 · 2026-07-27
- Tokyo Agent Forge hackathon shipped production-ready AI agents in one day — DavidBennett__ · 2026-07-27
- A high-school genius meme ends with four people at Anthropic — hingeloss · 2026-07-27
- Organizations may already be the planet’s superintelligences — eldonredwards · 2026-07-27